Amanat Acquisition Corp filed a Form 425 on October 27, 2026, disclosing that Corxel Pharmaceuticals, Inc. shared a LinkedIn post on October 26, 2026 in connection with their proposed business combination.

Key Highlights

  • Social media disclosure: Corxel Pharmaceuticals, Inc. ("Corxel US") shared a post on LinkedIn on October 26, 2026 through its social media account relating to the proposed business combination with Amanat Acquisition Corp.
  • Registration statement planned: The parties intend to file a registration statement on Form S-4 with the SEC, which will include a preliminary proxy statement and prospectus.
  • Shareholder vote required: The business combination will be submitted to Amanat's shareholders for consideration, with proxy materials to be mailed after the Registration Statement is declared effective.
  • Product candidates named: The filing's forward-looking statements reference development, regulatory, manufacturing, and commercialization plans for product candidates CX11 and CX12.
  • Prior filings referenced: Amanat's final prospectus was filed with the SEC on May 20, 2026, and its initial public offering prospectus is dated May 18, 2026.
  • Company address: Amanat Acquisition Corp is located at 153 Central Avenue, C/O 56, Westfield, New Jersey 07091.

Amanat and Corxel US Advance Proposed Combination With Regulatory Filings Ahead

According to the filing, Amanat Acquisition Corp (NASDAQ:AMAN) disclosed that Corxel Pharmaceuticals, Inc., a party to the proposed business combination, used its LinkedIn account on October 26, 2026 to share a post about the transaction. The filing was made pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934. The subject company is identified as Amanat Acquisition Corp, with SEC File No. 001-43303.

The filing states that the parties to the Business Combination Agreement intend to file a registration statement on Form S-4 with the SEC, which will include a preliminary proxy statement for the solicitation of proxies from Amanat shareholders and a prospectus for securities expected to be issued in connection with the transaction. Once the Registration Statement is declared effective, the definitive proxy statement/prospectus and other relevant materials are to be mailed or otherwise made available to Amanat shareholders as of the applicable record date.

The filing's forward-looking statements section identifies Corxel US's pharmaceutical pipeline as part of the anticipated transaction, referencing product candidates CX11 and CX12, including the design, timing, enrollment, and results of clinical trials, as well as potential regulatory and commercialization plans for those candidates. The filing notes that forward-looking statements reflect the current expectations, estimates, and assumptions of the management of Amanat and Corxel US as of the date of the announcement, and "should not be relied upon as guarantees, assurances, predictions, definitive statements or probabilities of future events or performance." The filing further discloses risks including the possibility that the proposed transaction is delayed, restructured, or not completed, and that Nasdaq listing requirements may not be satisfied.

What Was Disclosed

Amanat Acquisition Corp filed a Form 425 reporting that Corxel Pharmaceuticals, Inc. published a LinkedIn post on October 26, 2026 relating to their proposed business combination, and providing information about the planned registration statement, shareholder vote process, and associated risks.